Currently, there are 10.62M common shares owned by the public and among those 10.57M shares have been available to trade.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The company’s stock has a 5-day price change of -33.68% and -84.15% over the past three months. HEPA shares are trading -78.39% year to date (YTD), with the 12-month market performance down to -96.58% lower. It has a 12-month low price of $0.10 and touched a high of $3.24 over the same period. HEPA has an average intraday trading volume of 20.95 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -38.23%, -67.10%, and -85.16% respectively.
Institutional ownership of Hepion Pharmaceuticals Inc (NASDAQ: HEPA) shares accounts for 14.69% of the company’s 10.62M shares outstanding.
It has a market capitalization of $1.08M and a beta (3y monthly) value of 1.40. The earnings-per-share (ttm) stands at -$4.39. Price movements for the stock have been influenced by the stock’s volatility, which stands at 22.51% over the week and 15.52% over the month.
Looking at the support for the HEPA, a number of firms have released research notes about the stock. ROTH Capital stated their Buy rating for the stock in a research note on July 20, 2020, with the firm’s price target at $14.
